Evidence for age-related differences in human fibrinogen

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 2, 2011, Pages 110-117

  Ignjatovic, Vera ^a,b   Ilhan, Aysel ^c   Monagle, Paul ^a,b,d  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b Department of Paediatrics ^*  (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

age related; children; fetal; fibrinogen

Indexed keywords

FIBRINOGEN;

ADULT; AGE DISTRIBUTION; AMINO ACID SEQUENCE; ANTICOAGULANT THERAPY; ARTICLE; COMPARATIVE STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MOLECULAR WEIGHT; NEWBORN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PURIFICATION;

ADULT; AGE FACTORS; AGING; CHILD; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; INFANT; INFANT, NEWBORN; MASS SPECTROMETRY; POLYMERIZATION; SIALIC ACIDS; THROMBIN TIME;

EID: 79951672148     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328343312f     Document Type: Article

References (25)

1. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson AD. Antithrombotic therapy in children: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:645-687.
2. Ignjatovic V, Furmedge J, Newall F, Chan A, Berry L, Fong C, et al. Age-related differences in heparin response. Thromb Res 2006; 118:741-745. (Pubitemid 44647091)
3. IgnjatovicV,Summerhayes R,Than J,Gan A, Monagle P.Therapeuticrange for unfractionated heparin therapy: age-related differences in response in children. J Thromb Haemost 2006; 4:2280-2283. (Pubitemid 44400313)
4. Newall F, Ignjatovic V, Summerhayes R, Gan A, Butt W, Johnston L, Monagle P. In vivo age dependency of unfractionated heparin in infants and children. Thromb Res 2009; 123:710-714.
5. Monagle P, Hagstrom J. Developmental haemostasis. In: Polin RA, editor. Fetalandneonatalphysiology. 3rd ed. St Louis: Elsevier; 2003. pp. 1435-1447.
6. Witt I, Muller H. Phosphorus and hexose content of human foetal fibrinogen. Biochim Biophys Acta 1970; 221:402-404.
7. Hamulyak K, Nieuwenhuizen W, Devilee PP, Hemker HC. Reevaluation of some properties of fibrinogen, purified from cord blood of normal newborns. Thromb Res 1983; 32:301-310. (Pubitemid 14239986)
8. Witt I, Muller H, Kunzer W. Evidence for the existence of foetal fibrinogen. Thromb Diath Haemorrh 1969; 22:101-109.
9. Miller BE, Tosone SR, Guzzetta NA, Miller JL, Brosius KK. Fibrinogen in children undergoing cardiac surgery: is it effective? Anesth Analg 2004; 99:1341-1346. (Pubitemid 39407278)
10. Martinez J, MacDonald KA, PalascakJE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983; 61:1196-1202. (Pubitemid 13099909)
11. Dang CV, Shin CK, Bell WR, Nagaswami C, Weisel JW. Fibrinogen sialic acid residues are low affinity calcium binding sites that influence fibrin assembly. J Biol Chem 1989; 264:15104-15108. (Pubitemid 19237344)
12. Maghzal GJ, Brennan SO,George PM.Thesialic acid contentof fibrinogen decreases during pregnancy and increases in response to fibrate therapy. Thromb Res 2005; 115:293-299.
13. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, et al. Developmental haemostasis. Impact for clinical haemostasis laboratories. Thromb Haemost 2006; 95:362-372.
14. Pappin DJ, Hojrup P, Bleasby AJ. Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol1993; 3:327-332.
15. Henschen-Edman AH. Fibrinogen noninherited heterogeneity and its relationship to function in health and disease. Ann N YAcad Sci 2001; 936:580-593. (Pubitemid 32613944)
16. Charlwood J, Bryant D, Skehel JM, Camilleri P. Analysis of N-linked oligosaccharides: progress towards the characterisation of glycoprotein-linked carbohydrates. Biomol Eng 2001; 18:229-240. (Pubitemid 32939342)
17. Robertson ER, KennedyJF. Glycoproteins: a consideration of the potential problems and their solutions with respect to purification and characterisation. Bioseparation 1996; 6:1-15. (Pubitemid 26311966)
18. Townsend RR, Hilliker E, Li YT, Laine RA, Bell WR, Lee YC. Carbohydrate structure of human fibrinogen. Use of 300-MHz 1H-NMR to characterize glycosidase-treated glycopeptides. J Biol Chem 1982; 257:9704-9710. (Pubitemid 13205136)
19. Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. Ann N YAcad Sci 1983; 408:28-43. (Pubitemid 13072024)
20. Fu Y, Zhang JZ, Redman CM, Grieninger G. Formation of the human fibrinogen subclass fib420: disulfide bonds and glycosylation in its unique (alphaE chain) domains. Blood 1998; 92:3302-3308. (Pubitemid 28492338)
21. MaurerMC, PengJL, An SS,TrossetJY, Henschen-Edman A,ScheragaHA. Structural examination of the influence of phosphorylation on the binding of fibrinopeptide A to bovine thrombin. Biochem 1998; 37:5888-5902. (Pubitemid 28196740)
22. Chandrasekhar N, Warren L, Osbahr AJ, Laki KL. Role of sialic acid in fibrinogen. Biochim Biophys Acta 1962; 63:337-339.
23. Nishibe H, Takahashi N. The release of carbohydrate moieties from human fibrinogen by almond glycopeptidase without alteration in fibrinogen clottability. Biochim Biophys Acta 1981; 661:274-279. (Pubitemid 12233436)
24. Raisys V, Molnar J, Winzler RJ. Study of carbohydrate release during the clotting of fibrinogen. Arch Biochem Biophys 1966; 113:457-460.
25. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol 1957; 17:237-246.